This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / GSK plc Cuts 350 R&D Jobs Globally
Business job cuts

GSK plc Cuts 350 R&D Jobs Globally

Analysis based on 9 articles · First reported Feb 02, 2026 · Last updated Feb 02, 2026

Sentiment
10
Attention
2
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market impact is mixed; while GSK plc is cutting jobs, it is also increasing R&D investment, signaling a strategic shift towards high-potential medicines. This could lead to short-term concerns about job losses but long-term optimism for GSK plc's pipeline and profitability.

Pharmaceuticals Biotechnology
Event Summary

GSK plc is implementing an overhaul of its research and development division, resulting in approximately 350 job cuts across the United States and United Kingdom. Around 50 UK jobs are being cut at the Stevenage R&D hub. These cuts are part of an ongoing strategy to eliminate duplicated roles following the merger of its vaccines and specialty medicines operations and the spin-off of Haleon in 2022. Despite the job reductions, GSK plc is significantly increasing its R&D investment, with plans to spend £6.4 billion in 2024, focusing on developing new medicines with multi-blockbuster potential before 2031. The changes are occurring under the leadership of new chief executive Luke Miels, who recently took over from Emma Walmsley.

Key Actions
90 GSK plc axing research and development jobs
80 GSK plc increasing R&D investment
60 Luke Miels took over as chief executive GSK plc
40 GSK plc spun off consumer healthcare business Haleon
Entities Involved
stock
GSK plc
GSK plc is undergoing an overhaul of its research and development division, leading to job cuts. Despite the cuts, GSK plc is increasing its R&D investment, focusing on new medicines with multi-blockbuster potential. The company expects revenue and operating profit growth.
Importance 100 Sentiment 10
per
Luke Miels
Luke Miels recently took over as chief executive of GSK plc and is overseeing the R&D overhaul and job cuts. He is preparing to unveil the group's annual results, which will be his first since taking the top job.
Importance 70 Sentiment 10
cnt
United Kingdom
The United Kingdom is one of the locations where GSK plc is cutting research and development jobs, with approximately 50 jobs initially cut in Stevenage.
Importance 30 Sentiment 0
cnt
United States
The United States is another location where GSK plc is cutting research and development jobs as part of its global overhaul.
Importance 30 Sentiment 0
stock
Haleon
Haleon was spun off from GSK plc in 2022 as part of GSK plc's restructuring, which is indirectly related to the current R&D overhaul.
Importance 10 Sentiment 0
per
Emma Walmsley
Dame Emma Walmsley was the previous chief executive of GSK plc, succeeded by Luke Miels at the start of the year.
Importance 10 Sentiment 0
Relationships
Luke Miels related ↔ GSK plc
Haleon related ↔ GSK plc
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.